Genfit is a French biopharmaceutical company founded in 1999 that focuses on developing therapeutic and diagnostic solutions for metabolic and liver diseases. The company's primary focus areas include non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and other liver conditions. Genfit has developed both therapeutic drug candidates and diagnostic tools, including biomarkers for liver disease progression. The company is publicly traded on Euronext Paris and NASDAQ, with a significant focus on addressing the growing global burden of liver diseases associated with metabolic disorders and obesity.
Genfit has received investment from 1 venture capital firm.
French biopharmaceutical company developing therapeutic and diagnostic solutions for metabolic and liver diseases, including NASH.
Genfit has received investment from Kurma Partners. These venture capital firms and investors provide both capital and strategic support.
Genfit has raised $400M in total funding, with their most recent round being a IPO. The company operates in the Biotech sector.
Genfit was founded in 1999 and is headquartered in Loos, France.
Genfit operates in the Biotech sector. French biopharmaceutical company developing therapeutic and diagnostic solutions for metabolic and liver diseases, including NASH.
